C5 and myasthenia gravis: More recent approaches include the use of complement inhibitors, specifically monoclonal antibodies targeting C5 (eculizumab), have been widely studied as a potential treatment and are considered as clinically beneficial for MG patients [304,305,306,307], and there are efforts to develop new monoclonal antibodies or small interfering RNAs (siRNAs) targeting the complement system [195,308,309,310].